Vanguard Group Inc Cullinan Oncology, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CGEM
# of Institutions
153Shares Held
66.5MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$52.3 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$39.3 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$30.1 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$26.4 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$24.3 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $312M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...